Archean Chemical Industries reported a 53.9% quarter-on-quarter jump in EBITDA for Q1 FY27, signaling a recovery in bromine pricing and volumes. While year-on-year profits faced pressure from logistics costs, the company’s subsidiary, Acume Chemicals, has reached operational break-even. Investors are now tracking the execution of the Sicsem expansion project and the recovery timeline for the core salts business.
Archean Chemical Industries (ACI) has reported a recovery in its operational performance for the first quarter of fiscal year 2027, despite facing significant year-on-year headwinds. The company’s earnings before interest, tax, depreciation, and amortization (EBITDA) dropped 13.9% compared to the same period last year, largely due to high logistics expenses and ongoing challenges within its salts business segment. However, the sequential performance showed a notable improvement, with EBITDA rising 53.9% quarter-on-quarter, driven by a rebound in bromine volumes and better market pricing.
Operational Milestones and Subsidiary Performance
A key focus for the company is its subsidiary, Acume Chemicals, which specializes in bromine derivatives. In a positive development, the subsidiary has achieved EBITDA break-even, moving away from its initial loss-making phase. To capitalize on this, the management has set a production goal to reach an annualised bromine capacity of 20 to 25 kilotons by the end of FY27. Success in these efforts is tied to maintaining a blended bromine price of approximately INR 300 per kilogram, which remains a critical factor for the company’s overall profit margins.
Capital Spending and Future Execution
The company is currently in the middle of significant capital investment, particularly regarding the Sicsem project. A major portion of this spending, estimated at 60% to 65% of the total, is planned for the current fiscal year. While this expansion is aimed at scaling capacity, it also represents a period of high cash outflow. Investors will be closely watching whether the company can execute these projects without further cost overruns, which could strain the balance sheet if demand for bromine derivatives does not grow as expected.
Market Context and Outlook
Following the recent financial update, ICICI Securities has adjusted its EBITDA estimates for the company for FY27 and FY28 downward by 17% and 6%, respectively, citing the impact of higher cost structures. The brokerage has also changed its valuation method to an Enterprise Value-to-EBITDA (EV/EBITDA) model, assigning a target price of INR 640 based on a 16x multiple of projected FY28 EBITDA.
Looking ahead, the recovery in the salts business is expected to become clearer from the third quarter of FY27 as the current logistics problems are addressed. Additionally, the trial runs for phase II of the Sulphate of Potash (SOP) production are slated for completion by December 2026. The ability of the company to meet these project deadlines while managing debt and raw material costs will be the primary monitorable for shareholders in the coming quarters.